N-Ethyl-N-phenylethylenediamine | 155595-62-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-Ethyl-N-phenylethylenediamine
• 英文别名: N-ethyl-N'-phenylethane-1,2-diamine
• CAS: 155595-62-3
• 化学式: C₁₀H₁₆N₂
• 分子量: 164.25
• InChiKey: TWRYNQMDXKYLPX-UHFFFAOYSA-N

物化性质

• 沸点：
  290.3±23.0 °C(Predicted)
• 密度：
  0.982±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  24.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-Ethyl-N-phenylethylenediamine 在 盐酸 、 溶剂黄146 、 三乙胺 、 锌 、 sodium nitrite 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 17.0h， 生成 methyl N-[2-(N-aminoanilino)ethyl]-N-ethylcarbamate
  参考文献：
  名称：

  5-Lipoxygenase Inhibitors:  Synthesis and Structure−Activity Relationships of a Series of 1-Aryl-2H,4H-tetrahydro-1,2,4-triazin-3-ones

  摘要：

  Synthetic routes were developed to access a variety of novel 1-aryl-2H,4H-tetrahydro-1,2,4-triazin-3-one analogs which were evaluated as 5-lipoxygenase (5-LO) inhibitors. The parent structure, 1-phenylperhydro-1,2,4-triazin-3-one (4), was found to be a selective inhibitor of 5-LO in broken cell, intact cell, and human blood assays with IC50 values of 5-21 mu M. In a rat anaphylaxis model, 4 blocked leukotriene formation with an ED(50) = 7 mg/kg when administered orally. Compound 4 exhibited selectivity for inhibition of 5-LO with little activity against related enzymes: 12-LO from human platelets, 15-LO from soybean, and cyclooxygenase (COX) from sheep seminal vesicle. In pilot subacute toxicity testing, 4 did not produce methemoglobinemia in rats (400 mg/kg po daily for 9 days) or in dogs (200 mg/kg po daily for 28 days). These results indicated that the triazinone structure provided a 5-LO inhibitor template devoid of the toxicity problems observed in the related phenidone (1) and pyridazinone (3) classes of 5-LO inhibitors. The parent compound 4 is a selective, orally bioavailable 5-LO inhibitor which can serve as a useful reference standard for in vivo pharmacological studies involving leukotriene-mediated phenonmena.

  DOI：

  10.1021/jm960372b
• 作为产物：
  描述：

  N-苯基乙二胺 在 lithium aluminium tetrahydride 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 32.0h， 生成 N-Ethyl-N-phenylethylenediamine
  参考文献：
  名称：

  5-Lipoxygenase Inhibitors:  Synthesis and Structure−Activity Relationships of a Series of 1-Aryl-2H,4H-tetrahydro-1,2,4-triazin-3-ones

  摘要：

  Synthetic routes were developed to access a variety of novel 1-aryl-2H,4H-tetrahydro-1,2,4-triazin-3-one analogs which were evaluated as 5-lipoxygenase (5-LO) inhibitors. The parent structure, 1-phenylperhydro-1,2,4-triazin-3-one (4), was found to be a selective inhibitor of 5-LO in broken cell, intact cell, and human blood assays with IC50 values of 5-21 mu M. In a rat anaphylaxis model, 4 blocked leukotriene formation with an ED(50) = 7 mg/kg when administered orally. Compound 4 exhibited selectivity for inhibition of 5-LO with little activity against related enzymes: 12-LO from human platelets, 15-LO from soybean, and cyclooxygenase (COX) from sheep seminal vesicle. In pilot subacute toxicity testing, 4 did not produce methemoglobinemia in rats (400 mg/kg po daily for 9 days) or in dogs (200 mg/kg po daily for 28 days). These results indicated that the triazinone structure provided a 5-LO inhibitor template devoid of the toxicity problems observed in the related phenidone (1) and pyridazinone (3) classes of 5-LO inhibitors. The parent compound 4 is a selective, orally bioavailable 5-LO inhibitor which can serve as a useful reference standard for in vivo pharmacological studies involving leukotriene-mediated phenonmena.

  DOI：

  10.1021/jm960372b

文献信息

• [EN] PREPARATION AND METHOD FOR USE IN THE TREATMENT OF RESPIRATORY DISEASES<br/>[FR] PRÉPARATION ET PROCÉDÉ D'UTILISATION POUR TRAITER DES MALADIES RESPIRATOIRES
  申请人：UNIV LAVAL

  公开号：WO2014138975A1

  公开（公告）日：2014-09-18

  The present disclosure relates to a novel active compound having the formula Ia: solid preparations, uses and methods for the treatment or prevention of respiratory diseases comprising said compound as well as process of preparation thereof.

  本公开涉及具有化学式Ia的新型活性化合物：固体制剂，用途和治疗或预防呼吸道疾病的方法，包括该化合物，并其制备方法。
• ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE
  申请人：Li Xiaoming

  公开号：US20080194545A1

  公开（公告）日：2008-08-14

  The present invention is directed to compounds of formula I, pharmaceutical compositions comprising the compounds, and methods for making and using the inventive compounds.

  本发明涉及式I的化合物，包括该化合物的药物组合物，以及制备和使用该创新化合物的方法。
• [EN] INHIBITORS OF HISTONE DEACETYLASE<br/>[FR] INHIBITEURS DE L'HISTONE DEACETYLASE
  申请人：METHYLGENE INC

  公开号：WO2004069823A1

  公开（公告）日：2004-08-19

  The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

  该发明涉及抑制组蛋白去乙酰化酶的技术。该发明提供了抑制组蛋白去乙酰化酶酶活性的化合物和方法。该发明还提供了治疗细胞增殖性疾病和病症的组合物和方法。
• PREPARATION AND METHOD FOR USE IN THE TREATMENT OF RESPIRATORY DISEASES
  申请人：UNIVERSITE LAVAL

  公开号：US20160046587A1

  公开（公告）日：2016-02-18

  The present disclosure relates to a novel active compound having the formula Ia: solid preparations, uses and methods for the treatment or prevention of respiratory diseases comprising said compound as well as process of preparation thereof.

  本公开涉及一种具有Ia式的新型活性化合物：固体制剂，以及包括该化合物的用于治疗或预防呼吸系统疾病的方法和过程的制备。
• Substituierte 4-Aminomethylenchromane bzw. -chromene, Verfahren zu ihrer Herstellung sowie ihre Verwendung in Arzneimitteln
  申请人：BAYER AG

  公开号：EP0114374A1

  公开（公告）日：1984-08-01

  Verbindungen der Formel mehrere Verfahren zu ihrer Herstellung durch Umsetzung von Chroman-4-aldehyden mit Aminen oder Aminomethylenchromanen bzw. Chromenen mit Carbonylverbindungen in Gegenwart von reduzierenden Agentien oder von Halogenmethylchromanen mit Aminen, sowie ihre Verwendung in Arzneimitteln.

  式的化合物 在还原剂存在下，通过铬-4-醛与胺或氨甲基铬或铬与羰基化合物的反应，或卤甲基铬与胺的反应制备它们的几种工艺，以及它们在药物中的用途。